Similar articles for PMID: 36759197

Year	Number of Results
1990	1
1995	1
1996	1
1998	5
1999	2
2000	2
2001	4
2002	3
2003	10
2004	7
2005	3
2006	2
2007	3
2008	2
2009	5
2010	1
2011	4
2012	4
2013	4
2014	1
2015	6
2016	2
2017	8
2018	6
2019	5
2020	7
2021	8
2022	5
2023	2
2024	0

1

Radioimmunoscintigraphy and Pretreatment Dosimetry of ¹³¹I-Omburtamab for Planning Treatment of Leptomeningeal Disease.

Pandit-Taskar N, Grkovski M, Zanzonico PB, Pentlow KS, Modak S, Kramer K, Humm JL. Pandit-Taskar N, et al. J Nucl Med. 2023 Jun;64(6):946-950. doi: 10.2967/jnumed.122.265131. Epub 2023 Feb 9. J Nucl Med. 2023. PMID: 36759197 Free PMC article.

2

Biodistribution and Dosimetry of Intraventricularly Administered ¹²⁴I-Omburtamab in Patients with Metastatic Leptomeningeal Tumors.

Pandit-Taskar N, Zanzonico PB, Kramer K, Grkovski M, Fung EK, Shi W, Zhang Z, Lyashchenko SK, Fung AM, Pentlow KS, Carrasquillo JA, Lewis JS, Larson SM, Cheung NV, Humm JL. Pandit-Taskar N, et al. J Nucl Med. 2019 Dec;60(12):1794-1801. doi: 10.2967/jnumed.118.219576. Epub 2019 Aug 12. J Nucl Med. 2019. PMID: 31405921 Free PMC article.

3

Biodistribution and Radiation Dosimetry of Intraperitoneally Administered ¹²⁴I-Omburtamab in Patients with Desmoplastic Small Round Cell Tumors.

Grkovski M, Modak S, Zanzonico PB, Carrasquillo JA, Larson SM, Humm JL, Pandit-Taskar N. Grkovski M, et al. J Nucl Med. 2022 Jul;63(7):1094-1100. doi: 10.2967/jnumed.121.262793. Epub 2021 Dec 2. J Nucl Med. 2022. PMID: 34857661 Free PMC article. Clinical Trial.

4

Phase 1 study of intraventricular ¹³¹I-omburtamab targeting B7H3 (CD276)-expressing CNS malignancies.

Kramer K, Pandit-Taskar N, Kushner BH, Zanzonico P, Humm JL, Tomlinson U, Donzelli M, Wolden SL, Haque S, Dunkel I, Souweidane MM, Greenfield JP, Tickoo S, Lewis JS, Lyashchenko SK, Carrasquillo JA, Chu B, Horan C, Larson SM, Cheung NV, Modak S. Kramer K, et al. J Hematol Oncol. 2022 Nov 12;15(1):165. doi: 10.1186/s13045-022-01383-4. J Hematol Oncol. 2022. PMID: 36371226 Free PMC article. Clinical Trial.

5

Targeted radioimmunotherapy for embryonal tumor with multilayered rosettes.

Bailey K, Pandit-Taskar N, Humm JL, Zanzonico P, Gilheeney S, Cheung NV, Kramer K. Bailey K, et al. J Neurooncol. 2019 May;143(1):101-106. doi: 10.1007/s11060-019-03139-6. Epub 2019 Mar 16. J Neurooncol. 2019. PMID: 30879172 Free PMC article.

6

IntraOmmaya compartmental radioimmunotherapy using ¹³¹I-omburtamab-pharmacokinetic modeling to optimize therapeutic index.

Yerrabelli RS, He P, Fung EK, Kramer K, Zanzonico PB, Humm JL, Guo H, Pandit-Taskar N, Larson SM, Cheung NV. Yerrabelli RS, et al. Eur J Nucl Med Mol Imaging. 2021 Apr;48(4):1166-1177. doi: 10.1007/s00259-020-05050-z. Epub 2020 Oct 13. Eur J Nucl Med Mol Imaging. 2021. PMID: 33047248 Free PMC article.

7

Biodistribution and Dosimetry of Indigenously Produced ¹³¹I-Rituximab in B-Cell Lymphoma: Pilot Study Estimating Patient-Specific Dose Comparing 2 Different Dosimetric Methods.

Adnan A, Deep K, Kameswaran M, Nikam D, Shanmukaih C, Dash A, Banerjee S, Basu S. Adnan A, et al. J Nucl Med Technol. 2019 Dec;47(4):292-299. doi: 10.2967/jnmt.118.216754. Epub 2018 Nov 9. J Nucl Med Technol. 2019. PMID: 30413603 Free article. Clinical Trial.

8

Radiolabeling, biodistribution, and dosimetry of (123)I-mAb 14C5: a new mAb for radioimmunodetection of tumor growth and metastasis in vivo.

Lahorte CM, Bacher K, Burvenich I, Coene ED, Cuvelier C, De Potter C, Thierens H, Van de Wiele C, Dierckx RA, Slegers G. Lahorte CM, et al. J Nucl Med. 2004 Jun;45(6):1065-73. J Nucl Med. 2004. PMID: 15181142 Free article.

9

Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.

Wiseman GA, White CA, Sparks RB, Erwin WD, Podoloff DA, Lamonica D, Bartlett NL, Parker JA, Dunn WL, Spies SM, Belanger R, Witzig TE, Leigh BR. Wiseman GA, et al. Crit Rev Oncol Hematol. 2001 Jul-Aug;39(1-2):181-94. doi: 10.1016/s1040-8428(01)00107-x. Crit Rev Oncol Hematol. 2001. PMID: 11418315 Clinical Trial.

10

Myeloablative 131I-tositumomab radioimmunotherapy in treating non-Hodgkin's lymphoma: comparison of dosimetry based on whole-body retention and dose to critical organ receiving the highest dose.

Rajendran JG, Gopal AK, Fisher DR, Durack LD, Gooley TA, Press OW. Rajendran JG, et al. J Nucl Med. 2008 May;49(5):837-44. doi: 10.2967/jnumed.107.043190. Epub 2008 Apr 15. J Nucl Med. 2008. PMID: 18413376 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

101 results

Results by year